Information and technology services company IMS Health has announced the immediate availability in the US of IDN Impact — a first-of-its-kind solution to measure, compare and prioritise the influence of Integrated Delivery Networks (IDNs) on life sciences brands. Combining a unique data set of IDN influence metrics with business intelligence software and local market analysis, IDN Impact enables life sciences organisations to more effectively shape and execute their commercial engagement actions.
This service for the first time provides visibility into how payers, providers and IDNs drive treatment preferences and protocols within local healthcare markets. Armed with a more complete understanding of these stakeholders and their influence on treatment decisions, commercial leaders can quickly adapt their strategies, align sales and marketing resources, invest more strategically and maximise market share.
IDNs bring together groups of hospitals, out-patient facilities and providers to deliver a continuum of care and improve healthcare performance through their distinct policies and practices. In the US, more than 80 percent of hospitals are part of an IDN and at least half of physicians are affiliated with one, creating a complex web of local dynamics that affect treatment practices and commercial strategies.
Powered by IMS Health's unparalleled data resources, technology and consulting expertise, IDN Impact enables commercial teams to measure the influence of IDNs based on factors that include market reach, favorability toward therapeutic classes or brands, and their collective and individual impact on affiliated providers' prescribing behaviors, all while accounting for local payer and plan influence on treatment decisions.
